

multimodal therapies with MT is feasible and could have additive, if not synergistic effects.

Disclosure of Interest no.

P137

MAIN TRIAL RESULTS OF THE EVAQ CLINICAL STUDY FOR THE Q REVASCULARIZATION SYSTEM IN ACUTE ISCHEMIC STROKE

¹Christophe Cognard, ²Brian Jankowitz, ³Lucas Elijovich, ⁴Benjamin Gory, ⁵Romain Bourcier, ⁶Xavier Barreau, ⁷Federico Di Maria, ⁸Laurent Spelle, ⁹Maxim Mokin, ¹⁰Adnan Siddiqui, ¹¹Jazba Soomro, ¹²Omer Eker, ¹³Clemens Schirmer, ¹⁴Ashutosh Jadhav, ¹⁵Hamza Shaikh, ¹⁶Charles Matouk, ¹⁷Michael Stiefel, ¹⁸M Taqi, ¹⁹Jean Darcourt, ²⁰Leon Ikka, ⁶Gaultier Marnat, ⁹Kunal Vakharia, ¹⁹Guillaume Bellanger, ⁶Florent Gariel, ⁷Alessandro Sgreccia, ⁵Pierre Louis Alexandre, ²¹Liang Liao, ²²Morgane Laubacher, ¹⁰Jason Davies, ¹⁹Anne-Christine Januel, ⁵Hubert Desal, ¹¹Osman Mir, ²²Roberto Riva, ⁷Silvia Pizzuto, ²³David Liebeskind. ¹Hôpital Purpan, CHU de Toulouse, Toulouse, France; ²JFK University Medical Center, Edison, USA; ³Semmes Murphey, Memphis, USA; ⁴CHRU de Nancy, NANCY, France; ⁵CHU de Nantes, Nantes, France; ⁶University Hospital of Bordeaux, Bordeaux, France; ⁷Hospital Foch, Suresnes, France; ⁸Bicetre Medical Center, Bicetre, France; ⁹University of South Florida, Tampa General, Tampa, USA; ¹⁰University at Buffalo, Jacobs Institute, Buffalo, USA; ¹¹Texas Stroke Institute, Plano, USA; ¹²Hospices Civils de Lyon, Bron, France; ¹³Geisinger, Wilkes-Barre, USA; ¹⁴Barrow Neurological Institute, Phoenix, USA; ¹⁵Cooper University Healthcare, Camden, USA; ¹⁶Yale University, New Haven, USA; ¹⁷Piedmont Health, Atlanta, USA; ¹⁸Vascular Neurology of Southern California, Thousand Oaks, USA; ¹⁹Hopital Purpan, CHU de Toulouse, Toulouse, France; ²⁰Bicetre Hospital, Bicetre, France; ²¹CHRU de Nancy, Nancy, France; ²²CHU Lyon, Bron, France; ²³Neurovascular Imaging Research Core, UCLA, Los Angeles, USA

10.1136/jnis-2024-ESMINT.173

Introduction The Q Revascularization System is a novel thrombectomy device which aims to improve aspiration efficacy by

increasing the system inner diameter. The larger diameter allows for greater impulse and acceleration of aspiration than traditional aspiration systems.


Aim of Study Report the results of the EVAQ clinical study, **Methods** EVAQ is a prospective, single arm study with CEC and Core Lab assessed endpoints studying Q for the primary treatment of LVOs within 8hrs of symptom onset. Primary efficacy and safety endpoints are final mTICI2b-3 and sICH. Pre-specified secondary endpoints include revascularization after use of Q, first pass reperfusion and mRS0-2 at 90 days.

Results The EVAQ study enrolled one hundred twenty-three subjects at 17 centers in France and the US from November 2020 to April 2023. Mean age was 68.3. Females were 52.8%. Mean NIHSS and ASPECTS were 15.8±5.9 and 8.1 ±1.5 respectively. Sites of large vessel occlusion treatment were Basilar 3.3%, ICA 13.9%, M1 MCA 64.2%, M2 MCA 17.1%, and other anterior location 1.6%. IV thrombolysis was administered in 55.5% of subjects. Onset to arterial puncture was 4.58 hours ±2.04.

The primary outcome, final mTICI2b-3 by independent imaging core lab, was achieved in 93.9% of subjects. CEC adjudicated sICH per ECASS was 6.5%. Revascularization after the use of Q alone was 78.8% and first pass success was 56.7%. Time from groin puncture to successful revascularization was a mean of 38.2 minutes.

Conclusion The novel Q Revascularization System is safe and effective for revascularization of Large Vessel Occlusions in acute ischemic stroke.

Disclosure of Interest no.



Abstract P137 Figure 1

Abstract P137 Table 1 Catheter system average inner diameter (ID)

Average ID	3F	4F	5F	6F
Q Catheter	0.077"	0.081"	0.083"	0.085"
Competitor	0.041"	0.043"	0.055"	0.070"

*All Q sizes are used with MIVI Super90 Guide Catheter